X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Sun Pharma with MYLAN INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs MYLAN (US) - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 SUN PHARMA   MYLAN
EQUITY SHARE DATA
    SUN PHARMA
Mar-18
MYLAN
Dec-14
SUN PHARMA/
MYLAN
5-Yr Chart
Click to enlarge
High Rs7014,075-   
Low Rs4332,872-   
Sales per share (Unadj.) Rs110.41,395.2-  
Earnings per share (Unadj.) Rs11.0168.1-  
Cash flow per share (Unadj.) Rs17.2270.5-  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs158.8693.5-  
Shares outstanding (eoy) m2,399.26378.37-   
Bonus/Rights/Conversions -OI-  
Price / Sales ratio x5.12.5 206.2%   
Avg P/E ratio x51.620.7 249.8%  
P/CF ratio (eoy) x32.912.8 256.2%  
Price / Book Value ratio x3.65.0 71.3%  
Dividend payout %18.20-   
Avg Mkt Cap Rs m1,360,0211,314,345 103.5%   
No. of employees `00017.825.0 71.2%   
Total wages/salary Rs m53,6710-   
Avg. sales/employee Rs Th14,890.921,115.7 70.5%   
Avg. wages/employee Rs Th3,017.10-   
Avg. net profit/employee Rs Th1,480.62,543.7 58.2%   
INCOME DATA
Net Sales Rs m264,895527,894 50.2%  
Other income Rs m8,388-3,077 -272.6%   
Total revenues Rs m273,282524,817 52.1%   
Gross profit Rs m56,081131,290 42.7%  
Depreciation Rs m14,99838,771 38.7%   
Interest Rs m5,17622,771 22.7%   
Profit before tax Rs m44,29566,671 66.4%   
Minority Interest Rs m0-274 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-9,5050-   
Tax Rs m8,4522,804 301.5%   
Profit after tax Rs m26,33863,593 41.4%  
Gross profit margin %21.224.9 85.1%  
Effective tax rate %19.14.2 453.8%   
Net profit margin %9.912.0 82.5%  
BALANCE SHEET DATA
Current assets Rs m316,359464,088 68.2%   
Current liabilities Rs m198,643362,824 54.7%   
Net working cap to sales %44.419.2 231.7%  
Current ratio x1.61.3 124.5%  
Inventory Days Days9578 121.5%  
Debtors Days Days108107 100.4%  
Net fixed assets Rs m213,178122,127 174.6%   
Share capital Rs m2,39918,668 12.9%   
"Free" reserves Rs m378,6060-   
Net worth Rs m381,006262,415 145.2%   
Long term debt Rs m17,721392,023 4.5%   
Total assets Rs m643,0281,056,984 60.8%  
Interest coverage x9.63.9 243.3%   
Debt to equity ratio x01.5 3.1%  
Sales to assets ratio x0.40.5 82.5%   
Return on assets %4.98.2 60.0%  
Return on equity %6.924.2 28.5%  
Return on capital %10.013.6 73.6%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m10,6730-   
CASH FLOW
From Operations Rs m39,07269,392 56.3%  
From Investments Rs m-33,708-54,725 61.6%  
From Financial Activity Rs m-15,393-18,285 84.2%  
Net Cashflow Rs m-7,359-3,617 203.4%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 68.38 Rs / USD

Compare SUN PHARMA With: ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare SUN PHARMA With: ELDER PHARMA  ALEMBIC PHARMA  VENUS REMEDIES  CIPLA  SANOFI INDIA  



Today's Market

Indian Indices Continue Momentum; Sensex Ends 268 Points Higher(Closing)

After opening the day marginally higher, Indian share markets continued their momentum and ended their day on a positive note.

Related Views On News

SUN PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 265.5% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUN PHARMA has posted a net profit of Rs 15 bn (up 265.5% YoY). Sales on the other hand came in at Rs 77 bn (up 16.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 20, 2018 | Updated on Dec 20, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 110.7% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, SUN PHARMA has posted a net profit of Rs 1 bn (down 110.7% YoY). Sales on the other hand came in at Rs 69 bn (up 4.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

More Views on News

Most Popular

Are You Ready for the Big Nifty Move in the March Expiry?(Profit Hunter)

Mar 8, 2019

History suggests the Nifty could make a big move in March. Are you prepared to benefit from this opportunity?

Smallcaps Are Rallying and You Need to Make the Most of It Now(Profit Hunter)

Mar 7, 2019

Did you just miss the smallcap rally? Or is there still time to catch up? Read on for answers and more...

The One Sector to Bet on Today as India Grows into a 10 Trillion Dollar Economy(The 5 Minute Wrapup)

Mar 7, 2019

India's defence sector is suddenly under the spotlight. Can this sector ride along India's long-term growth story?

Is it the Right Time to Buy Mid and Small Caps Now?(The 5 Minute Wrapup)

Mar 6, 2019

Mid and Small Caps have underperformed large caps in the past year. Is the tide about to turn?

Elections Don't Matter!(The Honest Truth)

Mar 13, 2019

Ajit Dayal shows us why from the point of view of the Indian economy, elections don't matter.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Mar 19, 2019 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA - GSK PHARMA COMPARISON

COMPARE SUN PHARMA WITH

MARKET STATS